Positive TNK Study Results Fulfil Key FDA Requirement

• ARG-007 confirmed not to interfere with tenecteplase (TNK), meeting a critical FDA requirement and significantly de-risking ARG-007’s development for use alongside standard-of-care clot dissolving agents. • This drug-drug-interaction study compliments the previously completed study assessing ARG-007’s drug-drug interaction with alteplase, a standard of care clot dissolving drug similar to TNK, i